These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 28368903)
1. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903 [TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
3. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062 [TBL] [Abstract][Full Text] [Related]
4. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560 [TBL] [Abstract][Full Text] [Related]
5. Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases. Cabanie C; Biau J; Durando X; Mansard S; Molnar I; Chassin V; Verrelle P; Khalil T; Lapeyre M; Dupic G Cancer Radiother; 2021 Jul; 25(5):432-440. PubMed ID: 33836954 [TBL] [Abstract][Full Text] [Related]
6. Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma. Kelemen G; Együd Z; Dobi Á; Varga L; Kószó R; Borzási E; Paczona V; Végváry Z; Borzák F; Fodor E; Ócsai H; Baltás E; Oláh J; Hideghéty K Anticancer Res; 2024 Jan; 44(1):205-212. PubMed ID: 38159978 [TBL] [Abstract][Full Text] [Related]
8. The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. Lancellotta V; Del Regno L; Di Stefani A; Fionda B; Marazzi F; Rossi E; Balducci M; Pampena R; Morganti AG; Mangoni M; Lebbe C; Garbe C; Longo C; Schinzari G; Tagliaferri L; Peris K Radiol Med; 2022 Jul; 127(7):773-783. PubMed ID: 35606609 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. Schmidberger H; Rapp M; Ebersberger A; Hey-Koch S; Loquai C; Grabbe S; Mayer A Strahlenther Onkol; 2018 Dec; 194(12):1144-1151. PubMed ID: 30298365 [TBL] [Abstract][Full Text] [Related]
10. The changing paradigm of management in melanoma brain metastases. Ladwa R; Atkinson V Asia Pac J Clin Oncol; 2018 Dec; 14(6):453-458. PubMed ID: 29932306 [TBL] [Abstract][Full Text] [Related]
11. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Du Four S; Wilgenhof S; Duerinck J; Michotte A; Van Binst A; De Ridder M; Neyns B Eur J Cancer; 2012 Nov; 48(16):3045-51. PubMed ID: 22727601 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. Martin AM; Cagney DN; Catalano PJ; Alexander BM; Redig AJ; Schoenfeld JD; Aizer AA JAMA Oncol; 2018 Aug; 4(8):1123-1124. PubMed ID: 29327059 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Franceschini D; Franzese C; Navarria P; Ascolese AM; De Rose F; Del Vecchio M; Santoro A; Scorsetti M Cancer Treat Rev; 2016 Nov; 50():1-8. PubMed ID: 27566962 [TBL] [Abstract][Full Text] [Related]
14. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study. Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551 [TBL] [Abstract][Full Text] [Related]
15. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. Rahman R; Cortes A; Niemierko A; Oh KS; Flaherty KT; Lawrence DP; Sullivan RJ; Shih HA J Neurooncol; 2018 Jun; 138(2):299-306. PubMed ID: 29453679 [TBL] [Abstract][Full Text] [Related]
17. Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Du Four S; Janssen Y; Michotte A; Van Binst AM; Van den Begin R; Duerinck J; Neyns B Cancer Med; 2018 Oct; 7(10):4870-4879. PubMed ID: 30133176 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Glitza IC; Guha-Thakurta N; D'Souza NM; Amaria RN; McGovern SL; Rao G; Li J Melanoma Res; 2017 Dec; 27(6):580-584. PubMed ID: 28817446 [TBL] [Abstract][Full Text] [Related]
19. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. Weingarten N; Kruser TJ; Bloch O Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Stera S; Balermpas P; Blanck O; Wolff R; Wurster S; Baumann R; Szücs M; Loutfi-Krauss B; Wilhelm ML; Seifert V; Rades D; Rödel C; Dunst J; Hildebrandt G; Arnold A; Meissner M; Kähler KC Melanoma Res; 2019 Apr; 29(2):187-195. PubMed ID: 30802230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]